• #1163497
  • 156
  • Premier Biotech #RT-CV19-20

Rapid Test Kit RightSign™ Antibody Test COVID-19 IgG / IgM Whole Blood / Serum / Plasma Sample 20 Tests

TEST KIT, COVID-19 IGG/IGM WHOLE BLD/SERUM PLASMA

Features
  • Testing of serum, plasma and venous whole blood specimens is limited to laboratories certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C. 263a, that meet requirements to perform moderate or high complexity testsAND NO LONGER AVAILABLE
  • Testing of fingerstick whole blood specimens is limited to laboratories certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C. §263a, that meet the requirements to perform high, moderate or waived complexity tests
  • Testing of fingerstick whole blood specimens is authorized for use at the Point of Care (POC), i.e., in patient care settings operating under a CLIA Certificate of Waiver, Certificate of Compliance, or Certificate of Accreditation
  • More …
  Log In to Order
or

Professionals Also Viewed


Product Specifications


McKesson #1163497
Manufacturer #RT-CV19-20
BrandRightSign™
ManufacturerPremier Biotech
Country of OriginUnknown
ApplicationRapid Test Kit
CLIA ClassificationCLIA Waived for Fingerstick Whole Blood
Contents(20) Cassettes, 1 X 3 mL Buffer, (20) Capillaries, Package Insert, Procedure Card, (20) Lancets, (20) Pads
For Use WithFor the Qualitative Detection of SARS-CoV-2 Antibodies in Whole Blood, Serum or Plasma
Number of Tests20 Tests
Product DatingMcKesson Acceptable Dating: we will ship >= 90 days
Reading TypeVisual Read
Sample TypeWhole Blood / Serum / Plasma Sample
Storage RequirementsUSP Controlled Room Temperature
TechnologyLateral Flow Technology
Test FormatCassette Format
Test MethodRapid Chromatographic Immunoassay
Test NameCOVID-19 IgG / IgM
Test TypeAntibody Test
Time To Results10 Minute Results
UNSPSC Code41116205
Volume3 mL Buffer
Features
  • Testing of serum, plasma and venous whole blood specimens is limited to laboratories certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C. 263a, that meet requirements to perform moderate or high complexity testsAND NO LONGER AVAILABLE
  • Testing of fingerstick whole blood specimens is limited to laboratories certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C. §263a, that meet the requirements to perform high, moderate or waived complexity tests
  • Testing of fingerstick whole blood specimens is authorized for use at the Point of Care (POC), i.e., in patient care settings operating under a CLIA Certificate of Waiver, Certificate of Compliance, or Certificate of Accreditation
  • RightSign™ COVID-19 IgG/IgM Rapid Test Cassette is intended for use as an aid in identifying individuals with an adaptive immune response to SARS-CoV-2, indicating recent or prior infection
  • RightSign™ COVID-19 IgG/IgM Rapid Test Cassette should not be used to diagnose acute SARS-CoV-2 infection
  • Laboratories within the United States and its territories are required to report all positive results to the appropriate public health authorities
  • False positive results may occur due to cross-reactivity from pre-existing antibodies or other possible causes
  • Due to the risk of false positive results, confirmation of positive results should be considered using second, different IgG or IgM assay
  • RightSign™ COVID-19 IgG/IgM Rapid Test Cassette is a rapid lateral flow chromatographic immunoassay intended for the qualitative detection and differentiation of IgM and IgG antibodies to SARS-CoV-2 in in human venous whole blood (sodium heparin, EDTA, and sodium citrate), serum or plasma (sodium heparin, potassium EDTA and sodium citrate)
  • This test uses anti-human IgM antibody (test line IgM), anti-human IgG (test line IgG) and goat anti-mouse IgG (control line C) immobilized on a nitrocellulose strip
  • This test is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostic tests for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Act, 21 U.S.C. § 360bbb3(b)(1), unless the authorization is terminated or revoked sooner
More Information